Today, some major pharmaceutical companies continue to game the U.S. patent system by limiting generic competition while keeping drug prices high for millions of patients.  Big Pharma’s manipulation of patent laws prevent or delay generic medications from going to market which ultimately denies patients access to more affordable, life-saving, and quality of life enhancing drugs.  […]

Continue Reading

Part III: IPR & Opioid Addiction – Ending Brand Pharma’s Monopoly on Patents Some major pharmaceutical companies have enormous incentives to block market entry of lower-cost, generic drugs for as long as possible.  By taking advantage of certain rules or exploiting legal loopholes that extend a drug’s monopoly far beyond what Congress intended, millions of […]

Continue Reading

Part II: IPR & Zytiga – Competition Matters The rising costs of prescription drugs is one of the most important issues to Americans, especially as millions continue to grapple with financial hardships brought on by the coronavirus pandemic. Today, the U.S. pays some of the highest prices in the world for prescription drugs thanks in […]

Continue Reading

WASHINGTON, D.C. – The Coalition Against Patent Abuse (CAPA) – a diverse coalition of healthcare providers, consumer groups, patient advocacy organizations, free-market advocates and others – issued a statement today following the release of a Morning Consult survey which found that Americans overwhelmingly agree that it is time for Congress and the new Administration to reform […]

Continue Reading

Part I: IPR & Insulin – The True Value of PTAB Proceedings Year after year, pharmaceutical companies engage in anticompetitive strategies to game the U.S. patent system and keep drug prices high at the expense of patients. Even as millions of Americans grapple with financial hardships brought on by the COVID-19 pandemic, these pharmaceutical companies […]

Continue Reading

Patients Face Rising Costs for Critical Medications to Treat COVID-19 Related Effects WASHINGTON D.C. – Even before the COVID-19 pandemic, more than 58 million Americans struggled to afford their prescription drugs.  Now, the economic impact of the health crisis continues to leave millions of American workers, families and seniors struggling just to stay afloat.  Meanwhile, a new report released by Patients For […]

Continue Reading

WASHINGTON D.C. – As millions of Americans continue to grapple with high drug prices, a case before the U.S. Supreme Court surrounding the constitutionality of the Patent Trial and Appeal Board (PTAB) has taken on national significance for this growing national problem.  That’s why the Coalition Against Patent Abuse (CAPA) last week filed an amicus brief with […]

Continue Reading

WASHINGTON D.C. – As part of its ongoing campaign to safeguard the U.S. patent system and stop Big Pharma from gaming the system, the Coalition Against Patent Abuse (CAPA) this week filed comments with the United States Patent and Trademark Office (USPTO) outlining its concerns regarding the increased use of discretionary denials by the Patent Trial and Appeal […]

Continue Reading

Broad, Bipartisan Support Exists for Congress to Pass Drug Pricing Reforms Next Year and Reform the Patent System WASHINGTON D.C. – A new post-election survey of almost 2,000 registered voters nationwide conducted by Morning Consult finds that the rising cost of prescription drugs was a top issue for voters in this year’s election and moving forward […]

Continue Reading

Polls Show Rising Cost of Drugs Is One Of The Most Important Issues To U.S. Voters WASHINGTON, D.C. – The Coalition Against Patent Abuse (CAPA) – a diverse coalition of healthcare providers, consumer groups, patient advocacy organizations, free-market advocates and others – released a memo to the two major Presidential campaigns and Members of Congress today encouraging Washington […]

Continue Reading